A Randomized Phase II Trial Comparing a Calcineurin Inhibitor-Free Graft-Versus-Host Disease Prophylaxis Regimen with Post-Transplantation Cyclophosphamide and Abatacept to Standard of Care
Divya Koura(University of California San Diego), Kimberly McConnell(University of California San Diego), Joseph Maroge(University of California San Diego), Carolyn Mulroney(University of California San Diego Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), J Kyle Garrett(Moores Cancer Center), Caitlin Costello(University of California San Diego), Michelle Padilla(University of California San Diego), Aaron M. Goodman(University of California San Diego), Peggy Breslin(Moores Cancer Center), Edward D. Ball(Sheba Medical Center), James K. Mangan(UC San Diego Health System)
Cited by 2
Related Papers
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
|Molecular Cancer Therapeutics|2017|2.4k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|601
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
|Nature Reviews Clinical Oncology|2016|464